(266 days)
Yes.
The document explicitly states that DEEPECHO uses "machine learning techniques" and "artificial intelligence (AI) and machine learning algorithms" to analyze fetal ultrasound images and assist in measurements.
No
The device is described as an aid for analysis and measurement of fetal ultrasound images, not for direct treatment or therapy.
No
The device assists in measurements and view detection for fetal biometry but does not provide a diagnosis. It is intended for use by healthcare professionals as a "concurrent reading and measuring aid."
Yes
The device is explicitly described as "a cloud-based standalone software as a medical device (SaMD)". While it interfaces with ultrasound scanners by taking DICOM images or live streaming data, the core medical device itself is the software that analyzes these images using machine learning and provides measurements and view detection. The description does not mention any hardware components directly associated with the device that would classify it as something other than software-only.
No.
The device processes ultrasound images, which are medical images, not in vitro diagnostic specimens (e.g., blood, urine, tissue, etc.).
No
The letter does not contain any explicit statement that the FDA has reviewed and approved or cleared a PCCP for this specific device.
Intended Use / Indications for Use
DEEPECHO is intended to analyze fetal ultrasound images and clips using machine learning techniques to detect standard biometry views. Upon views detection, DEEPECHO assists in measurements computation of fetal biometric parameters (i.e., head circumference, abdominal circumference, femur length, and bi-parietal diameter).
The device is intended for use by qualified and appropriately trained healthcare professionals as a concurrent reading and measuring aid during the acquisition and interpretation of fetal ultrasound images of patients aged 18 years or older done between the 14th and the 41st weeks of pregnancy.
Product codes (comma separated list FDA assigned to the subject device)
IYN, IYO, QIH
Device Description
DEEPECHO is a cloud-based standalone software as a medical device (SaMD) that helps qualified healthcare professionals in the assessment of obstetrical images.
The device is intended for use by qualified and appropriately trained healthcare professionals, including but not limited to: radiologists, obstetricians, sonographers, maternal and fetal medicine specialists, obstetricians and gynecologists, as well as fetal surgeons. The device's application is intended for pregnant patients aged 18 years and older between the 14th and the 41st weeks of pregnancy.
DEEPECHO takes as an input either Digital Imaging and Communications in Medicine (DICOM) images or a live fetal ultrasound image streaming from ultrasound scanners. When DEEPECHO is in use, it allows healthcare professionals to browse fetal ultrasound images, identify views (cephalic, abdominal, and femoral) and suggest a placement for calipers on fetal ultrasound images of the identified views and compute biometrical measurements of the latter (HC (Head Circumference), BPD (Bi-parietal Diameter), FL (Femur Length), AC (Abdominal Circumference), GA (Gestational Age), EFW (Estimated Fetal Weight)).
When DEEPECHO is used during real time (i.e., during the examination) the device receives real-time image streaming from an ultrasound machine and can be used to identify views (cephalic, abdominal, and femoral), and suggests a placement for calipers. These Ultrasound images are acquired using an HDMI cable that is plugged into the local device (e.g., computer, tablet) running DEEPECHO, through an HDMI to USB Video Capture. Note that the device cannot compute measurements in real time as the real time data received from the ultrasound machine is a live stream video and not in a DICOM format. DICOM data is necessary to automatically compute biometrical measurements.
Additionally, DEEPECHO handles patient and exam management by allowing healthcare professionals to create, update, and archive records. When DICOM files are uploaded post-examination, the software either links the exam to an existing patient record or automatically generates a new one from the DICOM files' metadata. It enables healthcare professionals to track a patient's history, including exams, reports, and all information directly inputted to the platform.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Mentions "machine learning techniques" and "Artificial Intelligence".
Input Imaging Modality
Ultrasound
Anatomical Site
Fetus (Cephalic, Abdominal, Femoral views)
Indicated Patient Age Range
Pregnant patients aged 18 years or older.
Intended User / Care Setting
Qualified and appropriately trained healthcare professionals including radiologists, obstetricians, sonographers, maternal and fetal medicine specialists, obstetricians and gynecologists, and fetal surgeons.
Description of the training set, sample size, data source, and annotation protocol
Not Found. The document states: "No training data, patients, or clinical sites overlapped with the test dataset. Training data were obtained from two Roshan MFM clinics in New York City and selected sites in Morocco."
Description of the test set, sample size, data source, and annotation protocol
The bench testing dataset consisted of 417 ultrasound studies collected from 15 clinical sites across the United States, Mexico, and Morocco. Following the application of predefined exclusion criteria, including corrupted files and incomplete views, the final analysis population included 397 subjects, contributing a total of 23,544 de-identified 2D grayscale ultrasound images. Clinical sites included both tertiary maternal-fetal medicine practices and community-based health settings. Each image was independently reviewed by three ARDMS-certified sonographers with a minimum of five years of clinical ultrasound experience. All images were annotated using the CVAT platform by three independent ARDMS-certified sonographers with at least five years of experience. For continuous measurement endpoints, the ground truth was calculated as the arithmetic mean of three independent caliper placements. For classification endpoints, ground truth was based on unanimous agreement across reviewers. Inter-reader agreement for continuous outcomes exceeded ICC > 0.99. Test data were acquired from separate sites in the United States, Mexico, and Morocco, including Seattle (WA), Garden City (NY), Union (NJ), Honesdale (PA), Chiapas (Mexico), and Casablanca (Morocco).
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Study Type: Stand-alone assessment comparing the performance of the DEEPECHO software to a ground truth of annotations by qualified experts.
Sample Size: 397 subjects, contributing a total of 23,544 de-identified 2D grayscale ultrasound images.
Standalone Performance: Comparison of femur length, head circumference, abdominal circumference, biparietal diameter measurements using Deming regression; Sensitivity and specificity of each view identification for Abdominal, Cephalic, and Femoral views.
Key Results:
Measurements:
- Femur Length: Point Estimate (Intercept) = 0.003 (95% CI: -0.020, 0.025), Point Estimate (Slope) = 0.969 (95% CI: 0.966, 0.973)
- Head Circumference: Point Estimate (Intercept) = -0.360 (95% CI: -0.462, -0.0258), Point Estimate (Slope) = 1.026 (95% CI: 1.022, 1.031)
- Abdominal Circumference: Point Estimate (Intercept) = -0.017 (95% CI: -0.101, 0.065), Point Estimate (Slope) = 1.017 (95% CI: 1.013, 1.021)
- Biparietal Diameter: Point Estimate (Intercept) = -0.165 (95% CI: -0.203, -0.125), Point Estimate (Slope) = 1.020 (95% CI: 1.015, 1.025)
View Identification:
- Abdominal View: Sensitivity = 86.9% (83.8% - 89.7%), Specificity = 96.8% (96.4% - 97.2%)
- Cephalic View: Sensitivity = 98.2% (97.4% - 99%), Specificity = 94.8% (94.2% - 95.3%)
- Femoral View: Sensitivity = 91.8% (89% - 94.2%), Specificity = 97.4% (97% - 97.8%)
Worst-case analysis and subgroup analyses were also performed, demonstrating robust performance.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Femur Length:
- Intercept: 0.003 (95% CI: -0.020, 0.025)
- Slope: 0.969 (95% CI: 0.966, 0.973)
Head Circumference:
- Intercept: -0.360 (95% CI: -0.462, -0.0258)
- Slope: 1.026 (95% CI: 1.022, 1.031)
Abdominal Circumference:
- Intercept: -0.017 (95% CI: -0.101, 0.065)
- Slope: 1.017 (95% CI: 1.013, 1.021)
Biparietal Diameter:
- Intercept: -0.165 (95% CI: -0.203, -0.125)
- Slope: 1.020 (95% CI: 1.015, 1.025)
Abdominal View:
- Sensitivity: 86.9% (83.8% - 89.7%)
- Specificity: 96.8% (96.4% - 97.2%)
Cephalic View:
- Sensitivity: 98.2% (97.4% - 99%)
- Specificity: 94.8% (94.2% - 95.3%)
Femoral View:
- Sensitivity: 91.8% (89% - 94.2%)
- Specificity: 97.4% (97% - 97.8%)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1550 Ultrasonic pulsed doppler imaging system.
(a)
Identification. An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.
FDA 510(k) Clearance Letter - DEEPECHO
Page 1
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
Doc ID # 04017.07.05
May 23, 2025
DeepEcho
Youssef Bouyakhf
Chief Executive Officer
555 East Loockerman Street
DOVER, DE 19901
Re: K242594
Trade/Device Name: DEEPECHO
Regulation Number: 21 CFR 892.1550
Regulation Name: Ultrasonic Pulsed Doppler Imaging System
Regulatory Class: Class II
Product Code: IYN, IYO, QIH
Dated: April 23, 2025
Received: April 23, 2025
Dear Youssef Bouyakhf:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
Page 2
K242594 - Youssef Bouyakhf
Page 2
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
Page 3
K242594 - Youssef Bouyakhf
Page 3
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
JULIE SULLIVAN -S
Julie Sullivan, Ph.D.
Director
DHT8C: Division of Radiological Imaging and Radiation Therapy Devices
OHT8: Office of Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
Page 4
FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services (301) 443-6740 EF
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.
510(k) Number (if known): K242594
Device Name: DEEPECHO
Indications for Use (Describe)
DEEPECHO is intended to analyze fetal ultrasound images and clips using machine learning techniques to detect standard biometry views. Upon views detection, DEEPECHO assists in measurements computation of fetal biometric parameters (i.e., head circumference, abdominal circumference, femur length, and bi-parietal diameter).
The device is intended for use by qualified and appropriately trained healthcare professionals as a concurrent reading and measuring aid during the acquisition and interpretation of fetal ultrasound images of patients aged 18 years or older done between the 14th and the 41st weeks of pregnancy.
Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Page 5
510(k) Summary – K242594
1. SUBMITTER INFORMATION
Applicant: DeepEcho
Address: 555 East Loockerman Street; Dover, DE USA 19901
Contact: Youssef Bouyakhf
Phone: +447767643525
Email: youssef.bouyakhf@deepecho.io
2. CORRESPONDENT INFORMATION
Contact: Youssef Bouyakhf
Title: Chief Executive Officer
Firm: DeepEcho
3. DATE PREPARED: May 21, 2025
4. DEVICE INFORMATION
Device Name: DEEPECHO
Common Name: Fetal ultrasound analysis software
Regulation Number: 892.1550
Regulation Name: Ultrasonic pulsed doppler imaging system
Primary Product Code: IYN
Regulatory Class: II
Secondary Product Codes: IYO, QIH
5. PREDICATE AND REFERENCE DEVICES INFORMATION
Primary Predicate Device Name: SonioDetect
510(k) Number: K230365
Manufacturer: IYN
Reference Device Name: G8 (specifically the Biometry Assist feature)
510(k) Number: K223387
Manufacturer: Samsung Medison Co., Ltd.
Page 6
510(k) Summary – K242594
6. DEVICE DESCRIPTION
DEEPECHO is a cloud-based standalone software as a medical device (SaMD) that helps qualified healthcare professionals in the assessment of obstetrical images.
The device is intended for use by qualified and appropriately trained healthcare professionals, including but not limited to: radiologists, obstetricians, sonographers, maternal and fetal medicine specialists, obstetricians and gynecologists, as well as fetal surgeons. The device's application is intended for pregnant patients aged 18 years and older between the 14th and the 41st weeks of pregnancy.
DEEPECHO takes as an input either Digital Imaging and Communications in Medicine (DICOM) images or a live fetal ultrasound image streaming from ultrasound scanners. When DEEPECHO is in use, it allows healthcare professionals to browse fetal ultrasound images, identify views (cephalic, abdominal, and femoral) and suggest a placement for calipers on fetal ultrasound images of the identified views and compute biometrical measurements of the latter (HC (Head Circumference), BPD (Bi-parietal Diameter), FL (Femur Length), AC (Abdominal Circumference), GA (Gestational Age), EFW (Estimated Fetal Weight)).
When DEEPECHO is used during real time (i.e., during the examination) the device receives real-time image streaming from an ultrasound machine and can be used to identify views (cephalic, abdominal, and femoral), and suggests a placement for calipers. These Ultrasound images are acquired using an HDMI cable that is plugged into the local device (e.g., computer, tablet) running DEEPECHO, through an HDMI to USB Video Capture. Note that the device cannot compute measurements in real time as the real time data received from the ultrasound machine is a live stream video and not in a DICOM format. DICOM data is necessary to automatically compute biometrical measurements.
Additionally, DEEPECHO handles patient and exam management by allowing healthcare professionals to create, update, and archive records. When DICOM files are uploaded post-examination, the software either links the exam to an existing patient record or automatically generates a new one from the DICOM files' metadata. It enables healthcare professionals to track a patient's history, including exams, reports, and all information directly inputted to the platform.
7. INDICATIONS FOR USE
DEEPECHO is intended to analyze fetal ultrasound images and clips using machine learning techniques to detect standard biometry views. Upon views detection, DEEPECHO assists in measurements computation of fetal biometric parameters (i.e., head circumference, abdominal circumference, femur length, and bi-parietal diameter).
The device is intended for use by qualified and appropriately trained healthcare professionals as a concurrent reading and measuring aid during the acquisition and interpretation of fetal ultrasound images of patients aged 18 years or older done between the 14th and the 41st weeks of pregnancy.
Page 7
510(k) Summary – K242594
8. COMPARISON OF INTENDED USE AND TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
The table below compares the intended use and the technological characteristics of the subject device and predicate device.
Table 1: Comparator Table for Subject and Predicate Devices
| Category | Proposed Device (DEEPECHO) | Primary Predicate Device (Sonio Detect) | Reference Device (Biometry Assist feature in the V8 ultrasound system) |
|---|---|---|---|
| 510(k) Number | K242594 | K230365 | K223387 |
| Applicant | DeepEcho | Sonio | Samsung Medison Co. |
| Device Name | DEEPECHO | Sonio Detect | Biometry Assist feature in the V8 ultrasound system |
| Classification Regulation | 892.1550 - Accessory to Ultrasonic Pulsed Doppler Imaging System | ||
| 892.1560 - Accessory to Ultrasonic Pulsed Echo Imaging System | |||
| 892.2050 - Medical Image Management and Processing System | 892.1550 - Accessory to Ultrasonic Pulsed Doppler Imaging System | ||
| 892.1560 - Accessory to Ultrasonic Pulsed Echo Imaging System | |||
| 892.2050 - Medical Image Management and Processing System | 892.1550 - Ultrasonic Pulsed Doppler Imaging System | ||
| 892.1560 - Ultrasonic Pulsed Echo Imaging System | |||
| 892.1570 - Diagnostic Ultrasound Transducer | |||
| Product Code | IYN (Primary), IYO, QIH (Secondary) | IYN (Primary), IYO, QIH (Secondary) | IYN, IYO, ITX |
| Intended Users | Qualified and trained healthcare professionals including radiologists, obstetricians, sonographers, OB/GYNs, maternal and fetal medicine specialists (MFM specialists), and fetal surgeons | Qualified and trained healthcare professionals in a professional prenatal ultrasound imaging environment, including sonographers, MFMs, OB/GYNs, and fetal surgeons | Appropriately trained healthcare professionals qualified for direct use of medical devices |
| Patient Population | Pregnant patients aged 18 years and older, from 14 to 41 weeks of gestation | Pregnant patients across Trimester 1, Trimester 2, and Trimester 3, from 11 weeks to 37 weeks of gestation | Females of reproductive age |
| Imaging Modality | Ultrasound | Ultrasound | Ultrasound |
Page 8
510(k) Summary – K242594
| Category | Proposed Device (DEEPECHO) | Primary Predicate Device (Sonio Detect) | Reference Device (Biometry Assist feature in the V8 ultrasound system) |
|---|---|---|---|
| Views Detected | Cephalic view, Abdominal view, Femoral view | Transthalamic view, Transventricular view, Transcerebellar view, Four chambers, Profile or Nuchal translucency, Crown rump length, Sagittal spine, Abdominal circumference, Long bone, Upper lip, nose, and nostrils, Left ventricular outflow tract, Right ventricular outflow tract | 8 views recommended by the ISUOG and AIUM for biometric measurements and heart assessment. |
| Measurement Computation | Femur Length (FL), Abdominal circumference (AC), Amniotic Fluid Pocket's Depth, Head circumference (HC), Biparietal Diameter (BPD) Estimated Fetal Weight (EFW), Estimated Gestational Age (EGA) | None | Length measurement (FL, BPD) |
| Ellipse measurement (AC, HC) | |||
| Nuchal Translucency | |||
| Findings | Images labeled with correct views, caliper placement suggestion and measurement for circumference and distance for metrics such as HC, BPD, FL, AC, and examination reports | Images labeled with correct views, quality criteria identified as "Verified" when detected and "Not verified" when not detected | Images labeled with correct view |
| Caliper placement suggestion and measurement for circumference, distance and Nuchal Translucency | |||
| Editable examination report accessible on the console | |||
| Clinical Applications | Fetal/Obstetrics | Fetal/Obstetrics | Fetal/Obstetrics |
| Real-Time Assistance | Provides real-time identification of views and suggestions for caliper placement. | Primarily focused on verifying the quality criteria of detected views, ensuring that all required views are captured according to standardized protocols | Available on the Samsung V8 for automated view recognition and measurement. |
Page 9
510(k) Summary – K242594
| Category | Proposed Device (DEEPECHO) | Primary Predicate Device (Sonio Detect) | Reference Device (Biometry Assist feature in the V8 ultrasound system) |
|---|---|---|---|
| Algorithm Methodology | Artificial Intelligence for biometric measurement computations | Artificial Intelligence for lecture of biometrics and colorimetry for 3D and Doppler | Deep learning-based recognition algorithm |
| Platform and Accessibility | Cloud-based standalone software accessible from various devices, offering flexibility and ease of integration into different clinical environments | A SaaS solution with edge software requiring installation on a server connected to the ultrasound machine | Embedded in the ultrasound equipment. |
DEEPECHO and predicate and reference devices are intended to be used by trained healthcare providers in the analysis of fetal ultrasound images. The devices all use artificial intelligence (AI) and machine learning algorithms to assist healthcare professionals in the interpretation and analysis of these images.
Both DEEPECHO and Sonio Detect are capable of automatically detecting various standard views during fetal ultrasound examinations. The views identified by DEEPECHO are a subset of the views identified by Sonio Detect. Both systems also automatically identify standard fetal ultrasound views.
DEEPECHO and Sonio Detect both generate detailed reports based on the analysis of fetal ultrasound images.
Sonio Detect operates as a Software as a Service (SaaS) solution that requires installation of edge software on a server connected to the same network as the ultrasound machine. In contrast, DEEPECHO is a cloud-based standalone software that can be accessed from various devices, such as laptops, tablets, or desktops, without the need for local server installation. This difference does not raise different types of safety or effectiveness questions, as both deployment methods are commonly used in medical device software.
DEEPECHO differs from Sonio Detect in that it also computes a full set of biometric measurements—FL, AC, BPD, HC, EFW and EGA—which are included directly in its generated report; Sonio Detect does not compute any biometric measurements. In addition, DEEPECHO does not incorporate substructure detection or quality-criteria verification, both of which are provided by Sonio Detect. The Samsung Biometry Assist feature (the secondary reference device) likewise computes biometric measurements but does not automatically derive GA or EFW—users must select one of several well-established formulas to calculate those metrics.
Page 10
510(k) Summary – K242594
9. SUMMARY OF NON-CLINICAL PERFORMANCE TESTING
Software
Software was evaluated for a basic documentation level as recommended in the 2023 FDA guidance document Content of Premarket Submissions for Device Software Functions and software verification and validation data was performed.
Performance Testing
DeepEcho performed a stand-alone assessment comparing the performance of the DEEPECHO software to a ground truth of annotations by qualified experts.
Sample Size and Data Source
The bench testing dataset consisted of 417 ultrasound studies collected from 15 clinical sites across the United States, Mexico, and Morocco. Following the application of predefined exclusion criteria, including corrupted files and incomplete views, the final analysis population included 397 subjects, contributing a total of 23,544 de-identified 2D grayscale ultrasound images. Clinical sites included both tertiary maternal-fetal medicine practices and community-based health settings.
Relationship Between Patients and Images
Each subject contributed multiple images, including standard fetal biometry planes (biparietal diameter, head circumference, abdominal circumference, femur length) and non-standard views. Each image was independently reviewed by three ARDMS-certified sonographers with a minimum of five years of clinical ultrasound experience.
Demographics
The population included subjects with a mean maternal age of 29.4 years (range: 15–56) and a mean BMI of 26.8 (range: 17.5–52.5). The racial and ethnic distribution was as follows: 44% White non-Hispanic, 24% Hispanic/Latino, 13.3% Black non-Hispanic, 12.3% Asian, 4.5% Pacific Islander, and 1.9% American Indian or Alaskan Native.
Ultrasound Equipment and Protocols
DEEPECHO was only validated with the following ultrasound systems: Butterfly iQ3, GE Voluson (S8, S10, E6), Clarius HD3, and Philips IU22 and HD7. Image acquisition occurred during second and third trimester exams. All data were stored in DICOM, MP4 and PNG formats. Images from first trimester exams, Doppler imaging, and 3D acquisitions were excluded. No standardized acquisition protocol was enforced across sites.
Truthing Process (Reference Standard Derivation)
All images were annotated using the CVAT platform by three independent ARDMS-certified sonographers with at least five years of experience. For continuous measurement endpoints, the ground truth was calculated as the arithmetic mean of three independent caliper placements. For classification endpoints, ground truth was based on unanimous agreement across reviewers. Inter-reader agreement for continuous outcomes exceeded ICC > 0.99.
Dataset Independence
Page 11
510(k) Summary – K242594
No training data, patients, or clinical sites overlapped with the test dataset. Training data were obtained from two Roshan MFM clinics in New York City and selected sites in Morocco. Test data were acquired from separate sites in the United States, Mexico, and Morocco, including Seattle (WA), Garden City (NY), Union (NJ), Honesdale (PA), Chiapas (Mexico), and Casablanca (Morocco).
Summary Test Results
There were 6 primary endpoints in the DEEPECHO trial comparing DEEPECHO to ground truth measurements:
- Comparison of femur length
- Comparison of head circumference
- Comparison of abdominal circumference
- Comparison of biparietal diameter
- Sensitivity of each view identification
- Specificity of each view identification
The first four endpoints are concerned with accuracy of continuous measurements, Deming regression was performed to compare the DEEPECHO versus reader measurements.
Results are shown below.
Table 2: Primary Endpoints #1 - #4 Results
| Variable | N | Intercept | Slope | ||
|---|---|---|---|---|---|
| Point Estimate | 95% CI | Point Estimate | 95% CI | ||
| Femur Length | 431 | 0.003 | (-0.020, 0.025) | 0.969 | (0.966, 0.973) |
| Head Circumference | 858 | -.360 | (-0.462, -.0258) | 1.026 | (1.022, 1.031) |
| Abdominal Circumference | 499 | -.017 | (-0.101, 0.065) | 1.017 | (1.013, 1.021) |
| Biparietal Diameter | 858 | -.165 | (-0.203, -0.125) | 1.020 | (1.015, 1.025) |
Primary endpoints #5 and #6 evaluate the sensitivity and specificity of DEEPECHO in detecting anatomical views. To account for intra-subject correlation due to multiple observations per subject, a blockwise bootstrap method was used, with the subject as the resampling unit. The resulting point estimates reflect sample proportions, and the corresponding two-sided 95% confidence intervals were derived using this non-parametric approach.
Page 12
510(k) Summary – K242594
Table 3: Primary Endpoints #5 and #6 Results
| Endpoint of Interest | Statistics | |
|---|---|---|
| n/N | Point Estimate (95% CI)* | |
| Abdominal View | ||
| Sensitivity | 442/508 | 86.9% (83.8% - 89.7%) |
| Specificity | 7107/7340 | 96.8% (96.4% - 97.2%) |
| Cephalic View | ||
| Sensitivity | 992/1010 | 98.2% (97.4% - 99%) |
| Specificity | 6482/6838 | 94.8% (94.2% - 95.3%) |
| Femoral View | ||
| Sensitivity | 415/452 | 91.8% (89% - 94.2%) |
| Specificity | 7204/7396 | 97.4% (97% - 97.8%) |
*Confidence intervals were calculated using blocked bootstrapping
Worst-case analysis
A worst-case analysis was performed by imputing missing data as failures, based on the average number of observations per subject. After applying this conservative approach, the sensitivity and specificity for each anatomical view were recalculated. For the abdominal view, sensitivity was 82.7% (95% CI: 79.0%–85.8%) and specificity was 92.1% (95% CI: 91.4%–92.5%). For the cephalic view, sensitivity was 93.4% (95% CI: 91.5%–94.8%) and specificity was 90.2% (95% CI: 89.4%–90.6%). For the femoral view, sensitivity was 87.6% (95% CI: 83.5%–90.2%) and specificity was 92.7% (95% CI: 91.9%–93.2%).
Subgroup Analysis
Subgroup analyses were conducted to assess performance of view identification across maternal age, gestational age, BMI, racial/ethnic groups, acquisition sites, ultrasound system manufacturers, image types, image resolution, and operator image quality. For the cephalic view, both sensitivity and specificity remained high across all subgroups, with sensitivity typically above 95% and specificity above 93%. For the femoral view, sensitivity was also robust, typically exceeding 90%, and specificity remained above 95% across subgroups. In cases where point estimates were lower, this was primarily attributable to small denominators. Importantly, analyses stratified by ultrasound system type, image quality, and operator-assessed image quality showed no evidence of performance degradation.
Table 4: View Identification Primary Endpoint by Gestational Age Subgroups and Per Anatomical View
| Anatomical View | Measurement | 28 weeks |
|-----------------|-------------|-------------|------------|
| Abdominal | Sensitivity | 180/220 (81.8%) [0.761 - 0.867] | 221/233 (94.8%) [0.912 - 0.973] |
Page 13
510(k) Summary – K242594
| Anatomical View | Measurement | 28 weeks |
|-----------------|-------------|-------------|------------|
| | Specificity | 4576/4698 (97.4%) [0.969 - 0.978] | 2123/2227 (95.3%) [0.944 - 0.962] |
| Cephalic | Sensitivity | 564/580 (97.2%) [0.956 - 0.984] | 367/369 (99.5%) [0.981 - 0.999] |
| | Specificity | 4093/4338 (94.4%) [0.936 - 0.95] | 1995/2091 (95.4%) [0.944 - 0.963] |
| Femoral | Sensitivity | 174/197 (88.3%) [0.83 - 0.925] | 199/206 (96.6%) [0.931 - 0.986] |
| | Specificity | 4580/4721 (97%) [0.965 - 0.975] | 2211/2254 (98.1%) [0.974 - 0.986] |
Table 5: View Identification Primary Endpoint by BMI Subgroups and Per Anatomical View
| Anatomical View | Measurement | 18.5 - 25 | 25 - 30 | 30 - 35 | 35 - 40 | > 40 |
|---|---|---|---|---|---|---|
| Abdominal | Sensitivity | 39/48 (81.3%) [0.674 - 0.911] | 44/46 (95.7%) [0.852 - 0.995] | 17/17 (100%) [0.805 - 1] | 6/7 (85.7%) [0.421 - 0.996] | 3/4 (75%) [0.194 - 0.994] |
| Specificity | 903/926 (97.5%) [0.963 - 0.984] | 514/532 (96.6%) [0.947 - 0.98] | 166/171 (97.1%) [0.933 - 0.99] | 80/83 (96.4%) [0.898 - 0.992] | 43/45 (95.6%) [0.849 - 0.995] | |
| Cephalic | Sensitivity | 132/133 (99.2%) [0.959 - 1] | 86/87 (98.9%) [0.938 - 1] | 23/23 (100%) [0.852 - 1] | 13/14 (92.9%) [0.661 - 0.998] | 7/7 (100%) [0.59 - 1] |
| Specificity | 807/841 (96%) [0.944 - 0.972] | 475/491 (96.7%) [0.948 - 0.981] | 156/165 (94.5%) [0.899 - 0.975] | 73/76 (96.1%) [0.889 - 0.992] | 40/42 (95.2%) [0.838 - 0.994] | |
| Femoral | Sensitivity | 32/34 (94.1%) [0.803 - 0.993] | 34/34 (100%) [0.897 - 1] | 12/12 (100%) [0.735 - 1] | 5/5 (100%) [0.478 - 1] | 4/4 (100%) [0.398 - 1] |
| Specificity | 914/940 (97.2%) [0.96 - 0.982] | 535/544 (98.3%) [0.969 - 0.992] | 174/176 (98.9%) [0.96 - 0.999] | 83/85 (97.6%) [0.918 - 0.997] | 45/45 (100%) [0.921 - 1] |
Page 14
510(k) Summary – K242594
Table 6: View Identification Primary Endpoint by Manufacturer Subgroups and Per Anatomical View
| Anatomical View | Measurement | Butterfly | Clarius | General Electric | Philips Medical Systems |
|---|---|---|---|---|---|
| Abdominal | Sensitivity | 28/42 (66.7%) [0.505 - 0.804] | 8/9 (88.9%) [0.518 - 0.997] | 252/295 (85.4%) [0.809 - 0.892] | 154/162 (95.1%) [0.905 - 0.978] |
| Specificity | 77/77 (100%) [0.953 - 1] | 155/167 (92.8%) [0.878 - 0.962] | 5484/5628 (97.4%) [0.97 - 0.978] | 1386/1463 (94.7%) [0.935 - 0.958] | |
| Cephalic | Sensitivity | 37/37 (100%) [0.905 - 1] | 13/13 (100%) [0.753 - 1] | 630/635 (99.2%) [0.982 - 0.997] | 312/325 (96%) [0.933 - 0.979] |
| Specificity | 82/82 (100%) [0.956 - 1] | 141/163 (86.5%) [0.803 - 0.913] | 5088/5288 (96.2%) [0.957 - 0.967] | 1166/1300 (89.7%) [0.879 - 0.913] | |
| Femoral | Sensitivity | 33/40 (82.5%) [0.672 - 0.927] | 8/11 (72.7%) [0.39 - 0.94] | 207/216 (95.8%) [0.922 - 0.981] | 167/185 (90.3%) [0.851 - 0.941] |
| Specificity | 79/79 (100%) [0.954 - 1] | 152/165 (92.1%) [0.869 - 0.957] | 5590/5707 (97.9%) [0.975 - 0.983] | 1378/1440 (95.7%) [0.945 - 0.967] |
10. CONCLUSION
The results of the performance testing described above demonstrate that the DEEPECHO software is as safe and effective as the predicate device and supports a determination of substantial equivalence.